236 related articles for article (PubMed ID: 15781638)
1. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.
Schaefer KL; Wada K; Takahashi H; Matsuhashi N; Ohnishi S; Wolfe MM; Turner JR; Nakajima A; Borkan SC; Saubermann LJ
Cancer Res; 2005 Mar; 65(6):2251-9. PubMed ID: 15781638
[TBL] [Abstract][Full Text] [Related]
2. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
3. Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma.
Masuda T; Wada K; Nakajima A; Okura M; Kudo C; Kadowaki T; Kogo M; Kamisaki Y
Clin Cancer Res; 2005 Jun; 11(11):4012-21. PubMed ID: 15930335
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
6. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
Cheung KF; Zhao J; Hao Y; Li X; Lowe AW; Cheng AS; Sung JJ; Yu J
Cancer; 2013 Mar; 119(6):1217-26. PubMed ID: 23212831
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties.
Takahashi H; Fujita K; Fujisawa T; Yonemitsu K; Tomimoto A; Ikeda I; Yoneda M; Masuda T; Schaefer K; Saubermann LJ; Shimamura T; Saitoh S; Tachibana M; Wada K; Nakagama H; Nakajima A
Cancer Sci; 2006 Sep; 97(9):854-60. PubMed ID: 16805824
[TBL] [Abstract][Full Text] [Related]
8. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
11. The integrin, alpha6beta1, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells.
Carloni V; Mazzocca A; Pantaleo P; Cordella C; Laffi G; Gentilini P
Hepatology; 2001 Jul; 34(1):42-9. PubMed ID: 11431732
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.
Yu J; Shen B; Chu ES; Teoh N; Cheung KF; Wu CW; Wang S; Lam CN; Feng H; Zhao J; Cheng AS; To KF; Chan HL; Sung JJ
Hepatology; 2010 Jun; 51(6):2008-19. PubMed ID: 20512989
[TBL] [Abstract][Full Text] [Related]
13. Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma.
Wu CW; Farrell GC; Yu J
J Gastroenterol Hepatol; 2012 Nov; 27(11):1665-9. PubMed ID: 22742931
[TBL] [Abstract][Full Text] [Related]
14. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T
Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613
[TBL] [Abstract][Full Text] [Related]
15. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
Shen B; Chu ES; Zhao G; Man K; Wu CW; Cheng JT; Li G; Nie Y; Lo CM; Teoh N; Farrell GC; Sung JJ; Yu J
Br J Cancer; 2012 Apr; 106(9):1486-94. PubMed ID: 22472882
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
Li M; Lee TW; Yim AP; Mok TS; Chen GG
J Cell Physiol; 2006 Nov; 209(2):428-38. PubMed ID: 16883598
[TBL] [Abstract][Full Text] [Related]
18. In an adhesion dependent human gastric adenocarcinoma cell line, integrin ligation without adhesion rescues from anoikis but is not sufficient for cell cycle progression.
Caruso DA; McIntyre BW
Cell Death Differ; 2001 Jul; 8(7):665-78. PubMed ID: 11464211
[TBL] [Abstract][Full Text] [Related]
19. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells.
Schaefer KL; Takahashi H; Morales VM; Harris G; Barton S; Osawa E; Nakajima A; Saubermann LJ
Int J Cancer; 2007 Feb; 120(3):702-13. PubMed ID: 17096328
[TBL] [Abstract][Full Text] [Related]
20. An altered fibronectin matrix induces anoikis of human squamous cell carcinoma cells by suppressing integrin alpha v levels and phosphorylation of FAK and ERK.
Kamarajan P; Kapila YL
Apoptosis; 2007 Dec; 12(12):2221-31. PubMed ID: 17879163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
